Clinical Trial

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-20; most recent amendment 2026-03-04.
Status change: Not Yet Recruiting → Recruiting 2024-01-16
Trial Details
NCT Number NCT06055452
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Pre-Heart Failure, Hypertension
Enrollment 120 participants
Start Date 2024-01-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05